| Nov 9 |
Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Nov 8 |
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript
|
| Nov 8 |
Amneal Pharmaceuticals Non-GAAP EPS of $0.16 beats by $0.02, revenue of $702.5M beats by $8.77M
|
| Nov 8 |
Amneal Reports Third Quarter 2024 Financial Results
|
| Nov 7 |
Amneal Pharmaceuticals Q3 2024 Earnings Preview
|
| Oct 31 |
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211%
|
| Oct 21 |
Amneal gets FDA nod for NDA of its neuromuscular disorder treatment
|
| Oct 21 |
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
|
| Oct 9 |
Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Oct 8 |
Amneal to Report Third Quarter 2024 Results on November 8, 2024
|
